Target intelligence / Profile preview

Immunoglobulin heavy constant alpha 2 (IGHA2)

Target
IGHA2
Molecular classification
Immunoglobulin constant region, Antibody component
01

Overview

Immunoglobulin heavy constant alpha 2 (IGHA2) encodes the constant region of the heavy chain of IgA2, a major subclass of Immunoglobulin A that plays a crucial role in mucosal immunity. IgA2 is secreted primarily at mucosal surfaces and acts as a first line of defense against pathogens. The protein forms part of the antibody structure, contributing to effector functions such as neutralization of pathogens and facilitating their clearance. IGHA2 exhibits structural polymorphisms and works in concert with other immunoglobulin components. Diseases associated with IGHA2 primarily relate to immune disorders and infection, and it may also be implicated as a marker in some hematological cancers[1][2][4][5][7]. Key points: - IGHA2 is *not* a classic drug target like a receptor or enzyme but is an essential component of the adaptive immune system. - There are no approved drugs that target IGHA2 itself; therapeutic relevance is as a biomarker rather than a drug target[2][4].

Other names
Ig alpha-2 chain C regionA2MImmunoglobulin alpha 2 (A2M marker)Constant region of heavy chain of IgA2Ig alpha-2 chain C region BUTIg alpha-2 chain C region LAN
02

Biological functions

Humoral immune responseAntigen bindingImmune effector functionPositive regulation of respiratory burstGlomerular filtration
03

Disease associations

InfectionImmune disordersCancer (notably leukemia, acute lymphoblastic)
04

Safety considerations

Polymorphisms in IGHA2 may contribute to variability in immune responses and susceptibility to certain diseases; overall safety concerns are minimal as it is not a direct therapeutic target
05

Biomarkers

IgA2 levels in serum or secretions may serve as a marker in immune status and some diseases

Beyond the preview

Go deeper on Immunoglobulin heavy constant alpha 2 (IGHA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy constant alpha 2 (IGHA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call